ODI Pharma AB, a supplier of a wide range of medical cannabis products, has signed an exclusive agreement with Synoptis Pharma, part of the NEUCA group, a market leading pharmaceutical company in Eastern Europe, under which ODI Pharma is the exclusive supplier of medical cannabis products to Synoptis in 23 countries. The first product shipments have been completed and given a slim organization and scalable business model, ODI Pharma is expected to deliver profitable growth. With estimated net sales of SEK 127m by 2025/2026, and with an applied P/S multiple of 1.7x, a potential present value per share of SEK 10.7 is derived in a Base scenario.

Read the Equity Research Report Here

Analyst Group has interviewed ODI Pharma’s Chairman of the board, Volker Wiederrich. In the interview Volker tells us about where the company is today, the strategy going forward and gives three reasons as to why ODI Pharma is a good investment.

See the Interview Here

 About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.
Read more about Analyst Group (Swedish)
 
This is a press release from Analyst Group regarding the publication of an equity research report and an interview with ODI Pharma. Readers may assume that Analyst Group has received compensation for making the equity research report and the interview. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.